Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating BBT001, a drug candidate being developed for atopic dermatitis, in a Phase 1, randomized, double-blinded, placebo-controlled study. The study includes both healthy volunteers and adults with moderate to severe atopic dermatitis to assess safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity. The study has several parts single ascending dose SAD and multiple ascending dose MAD phases. Healthy volunteers will receive either a single or multiple doses of BBT001 or placebo, while patients with atopic dermatitis will receive multiple doses of BBT001 or placebo. These doses are administered under controlled conditions to compare effects and monitor responses. Participants will undergo safety monitoring through adverse event recording, blood tests, vital sign checks, physical exams, and ECG readings for up to 169 days following the first dose. Researchers will measure drug levels and immune responses to BBT001, as well as clinical activity related to atopic dermatitis. The study duration varies by part but involves multiple visits for assessments and monitoring.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are evaluating the NextAR navigation systems clinical utility in patients undergoing total knee arthroplasty for end-stage osteoarthritis. This prospective, randomized, single-blinded study aims to determine if personalized soft tissue balance data provided by the NextAR system can help prosthesis implants better resemble native knee alignment and improve patient outcomes and knee motion. Participants will undergo knee replacement surgery with either conventional instrumentation or the NextAR guidance system using the GMK Sphere implant. Clinical evaluations, including CT scans and X-rays, will be performed at various points before and after surgery. Outcomes assessed include soft tissue balance, knee kinematics via 3D gait analysis, and patient-reported measures such as the Forgotten Joint Score, Oxford Knee Score, International Knee Documentation Committee score, and quality of life questionnaires. Participants will be evaluated preoperatively and postoperatively at 6 weeks, 6 months, 1 year, and 2 years. Assessments include clinical questionnaires, imaging studies, and gait analysis to measure knee function and alignment. The primary outcome focuses on changes in the Forgotten Joint Score over time. The study duration spans up to two years following surgery with multiple follow-up visits to monitor clinical progress and knee performance.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating ways to improve hepatitis C virus HCV care in drug treatment clinics and needle and syringe programs in New South Wales and across Australia. The ETHOS II Project aims to develop a framework to establish HCV screening and treatment programs in these settings nationally. This collaborative research involves several health organizations and focuses on people with a history of injecting drug use or those receiving opioid substitution therapy. The study includes an intervention called campaign days where participants receive hepatitis C screening, liver fibrosis assessments using fibroscans, and clinical assessments. Participants also complete surveys and may consent to link their data with population databases. A sub-study involves collecting blood samples from some participants to evaluate new diagnostic tests for chronic HCV infection. Additionally, interviews with policymakers, clinicians, and patients will explore barriers to HCV care, and an education program will be developed to improve workforce knowledge and care quality. Participants will be recruited from drug treatment clinics, general practitioners with high case loads, and needle and syringe programs. They will undergo hepatitis C testing, fibroscans, clinical assessments, and complete questionnaires during the campaign days. Researchers will track how many participants start anti-HCV treatment each year for up to three years. The study also includes follow-up through medical record reviews to monitor outcomes and improve treatment access and delivery.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of TVB-3567, an oral capsule, in healthy adult participants with or without moderate to severe acne. The study is divided into four parts Part A and C involve randomized, double-blind, placebo-controlled investigations of single and multiple ascending doses in healthy participants Part B is an open-label study assessing the effect of food on a single dose and Part D is an open-label study in participants with moderate to severe acne. The study treatments include TVB-3567 administered orally as capsules compared with placebo in Parts A and C. Part B evaluates the impact of food on the drugs absorption. Part D involves two doses of TVB-3567 given to participants with acne to assess safety and biological markers. Each part has specific dosing regimens and assessments tailored to its objectives, with single or multiple dosing periods and crossover designs where applicable. Participants will undergo screening to confirm health status and eligibility, including age, body mass index, and acne diagnosis where applicable. During the trial, they will be monitored for adverse events and undergo pharmacokinetic and pharmacodynamic testing, including blood sampling to measure drug levels and biomarkers. Safety assessments and tolerability will be tracked from baseline to days following dosing in each part. The total study duration spans various periods depending on the part, with follow-up extending up to about two weeks after dosing.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating the use of cemiplimab, a drug that helps the immune system target cancer cells by binding to a protein called PD-1, to treat early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. The study compares the effects of cemiplimab injected directly into the cancer lesion with the standard treatment of surgery. The main goals include assessing side effects and determining how well cemiplimab works compared to surgery. Participants will receive either intralesional injections of cemiplimab or undergo primary surgery, which could involve Mohs surgery or other methods ensuring complete margin assessment. The study design is randomized and parallel, meaning participants are assigned to one of these two groups. Treatments and evaluations occur according to a protocol, with follow-up to monitor response and safety. During the trial, participants will be monitored through various assessments including measuring event-free survival up to three years, evaluating complete response of the target lesion at week 13, and checking for adverse events over three years. Measurements of surgical and biopsy defect sizes will also be recorded. The study involves regular visits and follow-up evaluations to track treatment effects and safety throughout participation, which lasts up to the study completion date in 2030.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.